638

IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, VOL. 62, NO. 2, FEBRUARY 2015

Adaptive Control of Bivalirudin in the Cardiac
Intensive Care Unit
Qi Zhao, Thomas Edrich, Member, IEEE, and Ioannis Ch. Paschalidisâˆ— , Fellow, IEEE

Abstractâ€”Bivalirudin is a direct thrombin inhibitor used in the
cardiac intensive care unit when heparin is contraindicated due
to heparin-induced thrombocytopenia. Since it is not a commonly
used drug, clinical experience with its dosing is sparse. In earlier
work [1], we developed a dynamic system model that accurately
predicts the effect of bivalirudin given dosage over time and patient
physiological characteristics. This paper develops adaptive dosage
controllers that regulate its effect to desired levels. To that end,
and in the case that bivalirudin model parameters are available,
we develop a Model Reference Control law. In the case that model
parameters are unknown, an indirect Model Reference Adaptive
Control scheme is applied to estimate model parameters first and
then adapt the controller. Alternatively, direct Model Reference
Adaptive Control is applied to adapt the controller directly without
estimating model parameters first. Our algorithms are validated
using actual patient data from a large hospital in the Boston area.
Index Termsâ€”Adaptive control, bivalirudin, parameter identification, pharmacokinetics.

I. INTRODUCTION
HE US health care system is viewed as costly and highly
inefficient. Among the many reform efforts, the meaningful use of Electronic Health Records is invariably seen as a key
to improving efficiency. In the hospital, the digitization of data
from medical devices enables the development of algorithms
that can automate decision making and facilitate treatment. This
is exactly the goal of this paper which focuses on automating
dosage decisions for a particular drugâ€”bivalirudinâ€”used in the
cardiac Intensive Care Unit (ICU).
Bivalirudin antagonizes the effect of thrombin in the bloodclotting cascade, thereby preventing complications from blood
clotting. It is currently FDA-approved for short-term anticoagulation of patients undergoing cardiac catheterization to prevent

T

Manuscript received January 28, 2014; accepted September 24, 2014. Date
of publication October 13, 2014; date of current version January 16, 2015.
This work was supported by the NIH/NIGMS under Grant R01-GM093147,
by the National Science Foundation under Grant CNS-1239021 and Grant IIS1237022, by the ARO under Grant W911NF-11-1-0227 and Grant W911NF12-1-0390, by the ONR under Grant N00014-10-1-0952, and by the STAR
(Surgical ICU TrAnslational Research) Center at Brigham and Womenâ€™s Hospital. Asterisk indicates corresponding author
Q. Zhao is with the Division of Systems Engineering, Boston University,
Boston, MA 02215 USA (e-mail: zhaoqi@bu.edu).
T. Edrich is with the Department of Anesthesiology, Perioperative Medicine,
and General Intensive Care Medicine, Salzburg General Hospital, Salzburg,
Austria (e-mail: tedrich@partners.org).
âˆ— I. C. Paschalidis is with the Department of Electrical & Computer Engineering, Division of Systems Engineering, and also with the Department of
Biomedical Engineering, Boston University, Boston, MA 02215 USA (e-mail:
yannisp@bu.edu).
Color versions of one or more of the figures in this paper are available online
at http://ieeexplore.ieee.org.
Digital Object Identifier 10.1109/TBME.2014.2362761

complications due to undesired blood clots [2]â€“[5]. Bivalirudin
is administered to patients who have a contraindication to heparin. It is infused continuously and is eliminated via the kidney
and by plasma protease-metabolism. It affects the coagulation
parameters Partial Thromboplastin Time (PTT) and the International Normalized Ratio in a dose-dependent fashion. The PTT
value is measured in seconds, and it will be used as the output
one wishes to regulate within a specific range.
Although not commonly used overall, bivalirudin is finding
increasing use in the ICU. Residents adjusting the infusion rate
of bivalirudin may have limited experience, thus, risking overor underdosing. Currently, the drug is regulated empirically or
with a very simple nomogram [6]. Adequate anticoagulation is
necessary to avoid the risk of clot formation, but overshooting increases the risk of bleeding. Complicating matters, there
is considerable inter- and intraindividual variability in the response to bivalirudin. Motivated by these challenges, in earlier work [1], [7], [8], we developed methods for predicting
future PTT values given past infusion rates and the patientâ€™s
renal and liver function characteristics. Related work has used
pharmacokinetic-pharmacodynamic models to model the effect
of various drugs, see, e.g., [9] and [10]. One of our methods
in [1] proposes an explicit dynamic system model which was
shown to produce quite accurate results when tested against
actual patient data.
In this paper, we pursue what we view as the natural next
step. Leveraging the dynamic system model from [1] and [8],
we seek to synthesize controllers that can regulate the infusion
rate to drive PTT within a desirable range. Other methodologies such as expert systems have also been used for controlling
some drugs [11]. We develop two types of control laws. First,
assuming that a dynamic system model that can predict PTT
given dosage is completely characterized, we develop a Model
Reference Control (MRC) law. Model parameters, however, may
be viewed as not known with certainty, which is due to modeling errors and inter- or intraindividual variability. To overcome
this problem, we develop an indirect Model Reference Adaptive Control (MRAC) law that identifies the model parameters
first and then adapts the controller in real time. Furthermore,
we develop a direct MRAC law that adapts the controller directly without estimating model parameters first, which is more
efficient. For each case, we present analytical and numerical
evidence showing that the controllers do drive PTT to the desirable range. Our numerical validation is in fact done using actual
patient data from the Brigham and Womenâ€™s Hospitalâ€”a large
hospital in the Boston area.
The remainder of this paper is organized as follows. Section II
presents the dynamic system model that predicts the effect of

0018-9294 Â© 2014 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission.
See http://www.ieee.org/publications standards/publications/rights/index.html for more information.

ZHAO et al.: ADAPTIVE CONTROL OF BIVALIRUDIN IN THE CARDIAC INTENSIVE CARE UNIT

639

1) Bival rate (mg/kg/h): the weight-based bivalirudin injection rate.
2) GFR (mL/min): the glomerular filtration rate.
3) SGOT (Units/L): the Serum Glutamic Oxaloacetic
Transaminase.
4) SGPT (Units/L): the Serum Glutamic Pyruvic Transaminase.
5) TBILI (mg/dL): total bilirubin.
6) ALB (g/L): Albumin.
7) PLT (K/mcL): Platelet count.
8) HCT (%): Hematocrit.
9) FIB (mg/dL): Fibrinogen.
More detailed description of these physiological variables can
be found in [1].
The model of Fig. 1 has a single outputâ€”the PTT valueâ€”
which is denoted by y(t). There is also a single state variable
denoted by x(t). Overall there are 12 unknown parameters, 11
of which correspond to the various gains and are denoted by
Î²i , i = 1, . . . , 11. The initial condition of the system is the 12th
unknown parameter and is denoted by x(0) (Î²12 ). The system
dynamics are
Fig. 1.

MISO dynamic system model.

xÌ‡(t) = Ax(t) + Bu(t)
y(t) = Cx(t) + Du(t)

bivalirudin given dosage and patient physiological information.
Section III presents the proposed control schemes; Section III-A
develops the MRC law, whereas Section III-B develops the indirect MRAC law based on the patient model but with unknown
parameters. Section III-C develops the direct MRAC, which is
more efficient in adapting the controller. Finally, concluding
remarks appear in Section IV.
Notation: We use bold letters to denote vectors and matrices;
typically, vectors are denoted by lower case letters and matrices
by upper case letters. Vectors are assumed to be column vectors
unless explicitly stated otherwise. For economy of space, we
write x = (x1 , . . . , xn ) for the column vector x âˆˆ Rn . In addition, we use lower case letters to denote time domain functions
(e.g., f (t)) and upper case letters to denote Laplace transforms
(e.g., F (s)).

II. DYNAMIC SYSTEM MODEL FORMULATION
A. Model
This section presents a multiple input single output (MISO)
dynamic system model that attempts to explicitly account for
the way bivalirudin affects PTT in patients. The model was
developed and validated in [1]; it is presented here briefly to
establish the notation and to set the stage for the control schemes
of Section III.
The key quantity (response) we would like to predict is the
PTT at each time t. The dynamic model structure is shown in
Fig 1. There are nine inputs which are denoted by ui (t), i =
1, . . . , 9 and correspond to important physiological variables
used as predictors. More specifically, inputs u1 (t), . . . , u9 (t)
respectively correspond to

(1)

where A = âˆ’Î²3 , B = [Î²1 0 Â· Â· Â· 0], C = Î²2 , and D =
[0 Î²4 . . . Î²11 ]. Clearly, this is a linear time invariant (LTI) dynamic system. The challenge is that we do not know the model
parameters, and we only have nonuniform sampled inputs u(t)
and clinical observation values y(t) at certain times t for each
patient. It is therefore necessary to translate the continuous-time
system dynamics to discrete-time dynamics before proceeding
with parameter identification.
B. Parameter Identification
Given the highly nonuniform sampled data, two methods were
introduced to identify model parameters in [1]. First, after converting to discrete-time dynamics, we formulated the parameter
identification problem as the nonlinear optimization problem of
minimizing some metric of fitness to a training set of sampled
data.
The dataset we used comes from the Surgical ICU Translational Research (STAR) Center at Brigham and Womenâ€™s Hospital in Boston. It consists of records for 233 patients including
the predictors and the output PTT value sampled (nonuniformly)
over time. We randomly split our dataset into a training set corresponding to 2/3 of the total (155 patients) and a test set corresponding to 1/3 of the total (78 patients). We use the former to
identify the unknown system parameters and the latter to evaluate the performance of the various control laws we will develop
in subsequent sections.
More specifically, let us use a subscript j to denote the model
primitives, i.e., the state xj (t), output yj (t), and inputs uj (t)
for each patient j = 1, . . . , N , where N denotes the number
of patients in the training set. To distinguish between measurements of yj (t) and predictions based on the system dynamics,
we use yj (t) for the former and yÌ‚j (t) for the latter. Suppose for

640

IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, VOL. 62, NO. 2, FEBRUARY 2015

Fig. 3.
Fig. 2. In this dynamic model, the bivalirudin infusion rate u(t) is the only
controllable input. d(t) is the linear combination of the rest of the inputs.

T

each patient j, we have Tj measurements at times t1j , . . . , tj j ,
where we adopt the convention t0j = 0 for all j. We can then
formulate a nonlinear optimization problem of minimizing the
least-square error
t

Tj

j
N 


(yÌ‚j (t) âˆ’ yj (t))2

j =1 t=t 1j

subject to the discretized version of the system dynamics. The
decision variables are x(0)(= x(t0j ) for all j) and the parameters
Î²i , i = 1, . . . , 11. One can easily substitute the expressions from
the constraints (the system dynamics) into the objective function and obtain a nonlinear optimization problem with no constraints other than some bounds on the decision variables. This
problem, however, is nonconvex. We applied a Quasi-Newton
method (BFGS) [12] to obtain optimal values for the model parameters. This yielded a population-wide model in the sense that
its parameters produced the best fit with the sampled data. Furthermore, and to accommodate variability across patients, we
used a recursive estimation method (Extended Kalman Filter)
to estimate the parameter values that best fit a given individual
patient in real time.
III. BIVALIRUDIN CONTROL SCHEME
We now turn to our primary goal of devising a proper controller to keep the PTT value in the range of 60â€“80 seconds (s).
According to clinical experience, this range is safe and optimal
for cardiac surgery patients. For the system we have defined
in (1), note that the only controllable part is the bivalirudin infusion rate. The rest of the inputs are indicators of patientsâ€™
liver (SGOT, SGPT, TBILI, ALB) and renal function (GFR)
and include some metrics related to the blood (PLT, HCT, FIB).
Arguably, these variables are not immediately affected by the
drug but change over a longer time scale than the one we focus on for controlling PTT through the infusion of bivalirudin.
Therefore, we consider them as noncontrollable and aggregate
them in a variable d(t) which is their linear combination with
the appropriate gains Î²4 , . . . , Î²11 (see Fig. 2).
Ideally, we want to design a reference model which can generate sufficient but safe PTT values driven by a reference input
signal. Based on the output of the reference model, we want to
drive our system to perform similarly to the reference model

MRAC structure.

by a proper control signal. Motivated by this, we adopt the socalled continuous-time MRAC scheme. Fig. 3 shows the general
structure of this control law. Wm (s) denotes an ideal reference
transfer function that can generate the desired reference output signal. The controllable system is represented by Gp (s, Î¸ âˆ—p ),
where Î¸ âˆ—p is a parameter vector. The objective is to design a
controller C(s, Î¸ âˆ—e ), parameterized by Î¸ âˆ—e , to generate the proper
control signals that can drive the controllable system to track
the reference output values.
Our first controller is an MRC law that is designed assuming
that the system parameters Î¸ âˆ—p are known.
A. Model Reference Control
By observing the system in Fig. 2, we can rewrite the dynamics of a particular patient as
xÌ‡p (t) = âˆ’Î²3 xp (t) + Î²1 u(t)

(2)

yp (t) = Î²2 xp (t) + d(t)

(3)

where we use u(t), xp (t), and yp (t) to denote the input signal
(bivalirudin infusion rate), the state variable,and the output
signal (PTT), respectively, and where d(t) = 9i=2 Î²i+2 ui (t).
Clinically, since the renal/liver functions and blood metrics of
patients do not vary much within a certain period, we do not
need to measure these physiological variables continuously, and
we assume that they are constant within the sample interval. By
observing the clinical data, we find that d(t) is a step-wise signal.
Ë™
Therefore, we assume that the first-order derivative of d(t) (d(t))
is 0 within the sample interval. By taking the derivative on both
sides of (3), using (2) to substitute for xÌ‡p (t), and using (3) to
eliminate xÌ‡p (t), we obtain
yÌ‡p (t) = âˆ’Î²3 yp (t) + Î²1 Î²2 u(t) + Î²3 d(t).

(4)

In the frequency domain, we have
Yp (s) =

Î²1 Î²2 U (s) + Î²3 D(s)
s + Î²3

where the system output yp (t) (Yp (s)), the input u(t) (U (s)),
and d(t) (D(s)) can be observed. Hence, in our setting, the
system transfer function is Gp (s, Î¸ âˆ—p ) = Yp (s)/U (s), and it is
parameterized by Î²1 , Î²2 , and Î²3 . In this case, Î¸ âˆ—p = (Î²1 , Î²2 , Î²3 ).
Next, we design a reference transfer function Wm (s). We
take Wm (s) to be a first-order LTI system driven by a reference
signal r(t):
Wm (s) =

bm
Ym (s)
=
R(s)
s + am

ZHAO et al.: ADAPTIVE CONTROL OF BIVALIRUDIN IN THE CARDIAC INTENSIVE CARE UNIT

which is equivalent to
yÌ‡m (t) = âˆ’am ym (t) + bm r(t),
Ym (s) =

or

(5)

bm
R(s)
s + am

for any bounded piecewise continuous signal r(t), where am >
0, bm = 0 are known. We assume that am , bm , and r(t) are
chosen so that ym (t) represents the desired output signal.
Before introducing the MRC law, we start with two definitions
and a theorem (proven in the Appendix).
Definition 1: A state xe is said to be an equilibrium state
of the system xÌ‡ = f (t, x), x(t0 ) = x0 , where x âˆˆ Rn , f :
T Ã— B(r) â†’ Rn , T = [t0 , âˆ), B(r) = {x âˆˆ Rn | x < r},
if f (t, xe ) â‰¡ 0 âˆ€t â‰¥ t0 . We assume that f is such that for every
x0 âˆˆ B(r) and every t0 âˆˆ [0, âˆ), the system possesses one and
only one solution x(t; t0 , x0 ).
Definition 2: A equilibrium state xe is exponentially stable if
there exits an Î± > 0, and for every  > 0 there exists Î´() > 0,
such that x(t; t0 , x0 ) âˆ’ xe  â‰¤ eâˆ’Î± (tâˆ’t 0 ) , âˆ€t â‰¥ t0 whenever
x0 âˆ’ xe  < Î´().
Theorem III.1: If we choose am > 0, bm = 0, and r(t) =
Cr (constant), the reference model equilibrium state ym e =
bm C r
a m is exponentially stable.
We will now design a proper controller u(t) such that all
signals in the closed-loop system are bounded, and the system
output yp (t) tracks the reference model output ym (t). The control law should be chosen so that the closed-loop plant transfer
function from the input r(t) to the output yp (t) is equal to the
reference model transfer function. Motivated by this, we propose the control law
C(s, Î¸ âˆ—e ) = U (s) = âˆ’k1âˆ— YP (s) + k2âˆ— R(s) âˆ’ k3âˆ— D(s)
or equivalently, in the time domain
uâˆ— (t) = âˆ’k1âˆ— yp (t) + k2âˆ— r(t) âˆ’ k3âˆ— d(t)

(6)

where k1âˆ— , k2âˆ— , k3âˆ— are controller coefficients chosen so that
bm
Yp (s)
Ym (s)
=
.
=
R(s)
s + am
R(s)

(7)

Eq. (7) is satisfied, if we select
k1âˆ— = âˆ’

1
(Î²3 âˆ’ am ),
Î²1 Î²2

MRC control signal becomes max{0, u(t)} with u(t) defined
as in (8).
We test the performance of the MRC on the dataset we described in Section II-B. We only use the test set (1/3 of the
total) for testing since the remaining training set was used for
model parameter identification. As mentioned previously, d(t)
(the linear combination of physiological variables at time t) is
a step-wise signal over time. By applying the parameter identification method outlined in Section II-B, we obtained both
population-wide parameter values and individual model parameter values.
We tested the MRC control law on a subset of patients, and
the results were qualitatively the same in each case. We report
results from a randomly selected patient who has identified
model parameters and available input data. To that end, we
set the reference parameters as am = 10, bm = 700, r(t) = 1.
Choosing these values keeps the reference PTT value to be 70s,
which is in the middle of the desirable range. We note that these
parameter values are simply an example, and physicians have
the freedom of selecting alternative values depending on the
stable value and response time they wish to achieve.
The effect of the MRC law (8) on this randomly selected
patient is shown in Fig. 4. It can be seen that driven by inputs
generated by the MRC law, the system output quickly converges to the reference output (top figure). The tracking error
(e(t) = yp (t) âˆ’ ym (t)) quickly converges to zero and remains
at zero (second figure). We also obtain the control signal which
corresponds to the bivalirudin infusion rate (third figure). The
MRC control law we introduced is robust to the uncontrollable
signal d(t) (bottom figure). Although d(t) changes over time,
the control signal can adapt and drive the system to track the
reference signal closely.
We next evaluate the performance of the MRC scheme on
all patients in the test set we described earlier. For performance
evaluation, we use three performance metrics. The first one is the
root mean square error (RMSE), which for patient i is defined
as


T
t i
 
1 i
i (t ))2
(ypi (ti ) âˆ’ ym
RMSEi = 
i
Ti
1
t=t i

k2âˆ— =

bm
,
Î²1 Î²2

k3âˆ— =

Î²3
Î²1 Î²2

which yields
u(t) =

641

bm
Î²3
1
(Î²3 âˆ’ am )yp (t) +
r(t) âˆ’
d(t)
Î²1 Î²2
Î²1 Î²2
Î²1 Î²2

(8)

provided of course that Î²1 , Î²2 , Î²3 = 0, i.e., the system is controllable. Such a transfer function matching guarantees that yp (t) =
ym (t) âˆ€t â‰¥ t0 , when yp (t0 ) = ym (t0 ) or |yp (t) âˆ’ ym (t)| â†’ 0
exponentially fast when ym (t0 ) = yp (t0 ) for any bounded reference signal r(t). We also note that, depending on the parameters
of some patients, this law may yield a negative control signal
which cannot be implemented in practice (corresponds to â€œextraction of bivalirudinâ€ from the patient). In such a case, we need
to set a lower threshold of zero for the control signal. The final

where t1i , . . . , tTi i are the time instants at which we adapt
the controller for patient i. We define RMSE for the whole
population ofpatients as the average per patient RMSE, i.e.,
t
RMSE= N1t N
i=1 RMSEi , where Nt is the number of patients
in the test set. We also define ÏƒE i to be the standard deviation
i
(t), t = t1i , . . . , tTi i , of patient
of the errors ei (t) = ypi (t) âˆ’ ym
i. Similarly, we define
ÏƒEt as the average standard deviation of
ÏƒE i â€™s, i.e., ÏƒE = N1t N
i=1 ÏƒE i .
To capture a notion of â€œrelativeâ€ error, we also compute the
normalized root mean square error (NRMSE) defined for each
patient i as


T
t i
 
1 i
i (t ))/y i (t )]2 .
NRMSEi = 
[(ypi (ti ) âˆ’ ym
i
m i
Ti
1
t=t i

642

Fig. 4.

IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, VOL. 62, NO. 2, FEBRUARY 2015

Effect of the MRC law derived for and applied to one randomly selected patient.

TABLE I
PERFORMANCE OF THE MRC (TEST SET)
value
RMSE
ÏƒE
NRMSE
ÏƒN E
RP

0.84
0.82
1.20%
1.17%
0%

As with the RMSE, we define the population-wide NRMSE as
the average of NRMSEi â€™s over the patients. Similarly, we also
define ÏƒNEi as the standard deviation of the normalized tracking
i
i
(t))/ym
(t) for patient i, and ÏƒNE as
errors ei (t) = (ypi (t) âˆ’ ym
the average of ÏƒNEi â€™s over the patients.
Furthermore, to illustrate the percentage of PTT outliers
which are outside clinically safe bounds, i.e., not in the interval [ym (t) âˆ’ 10, ym (t) + 10] during the transient and not in
the interval [60s, 80s] in steady state, the Risk Percentage (RP)
for patient i is defined as

RPi =

Nirisk
Ti

where Nirisk is the number of time instants t1i , . . . , tTi i at which
the PTT value of patient i is outside the safe bounds. Then,
RP is defined as the average of RPi â€™s over patients. We note
that this metric is from a clinical perspective the most important
in assessing the efficacy of our methods. Table I reports the
performance of the MRC law for the patients in the test set.
In summary, in the case that model parameters are known, the
MRC law tracks the reference signal quite well as demonstrated
by the low RMSE and NRMSE. The RP value is zero, which
completely assures clinical safety. The corresponding standard
deviations for RMSE and NRMSE are small as well.

B. Indirect MRAC
As we mentioned in Section there is significant patient variability in the response to bivalirudin. We have already established [1], that adapting model parameters to individual patients
leads to improved performance. This suggests that the model
structure is largely accurate but model parameters of an individual patient can deviate from population-wide parameter values.
To better assess the effect of this variability, we test the performance of the MRC law derived using parameter values of
a specific patient when applied to another patient with different model parameters. Fig. 5 plots the MRC law performance
for such a case. The top figure shows that there exists a large
gap between the reference output signal and the system output
signal. In addition, the system output is outside the safe range.
We also tested the MRC law derived using parameter values
of a specific patient against all patients in the test set. Table II
reports the results. We note that RMSE, NRMSE, and RP are
substantially higher (and clinically unacceptable) than those in
Table I. The difference of course is due to the fact the results of
Table I are obtained when using the MRC law with the correct
model parameters for each patient, whereas Table II results
apply the MRC law with parameters of some patient to another
patient. The small values of ÏƒE and ÏƒNE in Table II indicate
that performance of the MRC law when used with the wrong
parameters is consistently poor. This situation should obviously
be avoided because overdosing or underdosing is very dangerous
for the patients.
To address this important issue, we next develop a method
that first estimates the individual model parameters and then
adopts the MRC law we introduced using a certainty equivalence
principle [13]. Such a control scheme is called indirect MRAC
law.
By adding and subtracting âˆ’am yp (t) to (4), we can obtain
the State-Space Parametric Model:
yÌ‡p (t) = âˆ’am yp (t) + (am âˆ’ Î²3 )yp (t) + Î²1 Î²2 u(t) + Î²3 d(t).
(9)

ZHAO et al.: ADAPTIVE CONTROL OF BIVALIRUDIN IN THE CARDIAC INTENSIVE CARE UNIT

Fig. 5.

643

MRC law derived for one patient but applied to another patient.

TABLE II
PERFORMANCE OF THE INACCURATE MRC (TEST SET)

In this problem, we will estimate the product of Î²1 (t) and Î²2 (t)
instead of estimating them separately. The model estimation
error is e(t) = yp (t) âˆ’ yp (t) which implies:

value
RMSE
ÏƒE
NRMSE
ÏƒN E
RP

eÌ‡(t) = yË™p (t) âˆ’ yË™ p (t)

9.93
3.98
14.18%
5.68%
61.60%

= âˆ’am e(t) + Î²Ìƒ3 (t)(yp (t) âˆ’ d(t)) âˆ’ Î²Ìƒ12 (t)u(t)
where
Î²Ìƒ3 (t) = Î²3 (t) âˆ’ Î²3 ,

Based on (9), the series-parallel estimation model [14] is given
by
yË™ p (t) = âˆ’am yp (t) + (am âˆ’ Î²3 (t))yp (t)
+Î²1 (t)Î²2 (t)u(t) + Î²3 (t)d(t)

(10)

where yp (t) is an estimated value of yp (t), and Î²1 (t), Î²2 (t),
Î²3 (t) are estimates of the system parameters Î²1 , Î²2 , and Î²3 at
time t. Note that in (10), yp (t) is treated as an input available
for measurement. By using the certainty equivalence principle
[cf., (8)], we take the control scheme structure to be
u(t) = âˆ’k1 (t)yp (t) + k2 (t)r(t) âˆ’ k3 (t)d(t)
where
am âˆ’ Î²3 (t)
,
k1 (t) =
Î²1 (t)Î²2 (t)
k3 (t) =

Î²3 (t)
.
Î²1 (t)Î²2 (t)

(12)

(11)

Î²Ìƒ12 (t) = Î²1 (t)Î²2 (t) âˆ’ Î²1 Î²2 . (13)

We now choose a Lyapunov-like function
V (t) =

1
1
1
e(t)2 +
Î²Ìƒ3 (t)2 +
Î²Ìƒ12 (t)2
2
2Î³1
2Î³2

(14)

which, with Î³1 , Î³2 > 0, is nonnegative for all t. By taking the
derivative on both sides of (14), we obtain
1 Ëœ
1
Ë™
Ë™
Î²3 (t)Î²Ëœ3 (t) + Î²Ìƒ12 (t)Î²Ìƒ 12 (t)
Î³1
Î³2

	
1 ËœË™
2
Ëœ
= âˆ’am (e(t)) + Î²3 (t) e(t)(yp (t) âˆ’ d(t)) + Î²3 (t)
Î³1

	
1 Ë™
+Î²Ìƒ12 (t)
(15)
Î²Ìƒ (t) âˆ’ e(t)u(t) .
Î³2 12

VÌ‡ (t) = e(t)eÌ‡(t) +

Then, choosing
bm
k2 (t) =

Î²1 (t)Î²2 (t)

Ë™
Î²Ëœ3 (t) = âˆ’Î³1 (yp (t) âˆ’ d(t))e(t)

and

Ë™
Î²Ìƒ 12 (t) = Î³2 e(t)u(t)

leads to VÌ‡ (t) = âˆ’am e(t)2 â‰¤ 0. In addition, since Î²1 Î²2 and
Ë™
Ë™
Ë™
Î²3 are constants, (13) implies Î²Ìƒ 3 (t) = Î²3 (t) and Î²Ìƒ 12 (t) =

644

IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, VOL. 62, NO. 2, FEBRUARY 2015

d(Î²1 (t)Î²2 (t))/dt. It follows that we could estimate the model
parameters by
Ë™
Î²3 (t + Î”t) = Î²3 (t) + Î²3 (t)Î”t
d(Î²1 (t)Î²2 (t))
Î”t
(16)
Î²12 (t + Î”t) = Î²12 (t) +
dt
for small Î”t. Then, we can adapt the controller coefficients
recursively and control the system in real time by using
[cf., (11)]
am âˆ’ Î²3 (t)
bm
yp (t) +
r(t) âˆ’


Î²12 (t)
Î²12 (t)

Î²3 (t)
d(t).
Î²12 (t)
(17)
Similarly, as we did earlier for the MRC law, we will use the
control max{0, uâˆ— (t)} to avoid negative values.
Theorem III.2: Under the control law (17), the tracking error
converges to 0 as t â†’ âˆ.
Proof: By choosing such control law, VÌ‡ (t) = âˆ’am e(t)2 â‰¤
0, âˆ€t > t0 . Since V (t) is bounded from below and nonincreasing,

 âˆ it converges to a constant. This implies that
âˆ’am t 0 e2 (t)dt = V (âˆ) âˆ’ V (t0 ) is bounded, which in turn
implies that e(t) â†’ 0 as t â†’ âˆ according to Barbalatâ€™s lemma
Ë™
Ë™

[15]. It also follows that Î²Ìƒ 3 (t), Î²Ìƒ 12 (t) â†’ 0 as t â†’ âˆ.
One key flaw of the adaptive control law (17) is that the
boundness of control signal u(t) cannot be established unless
we show that k1 (t), k2 (t), k3 (t) are all bounded. However, such
a control law may generate estimates of Î²1 Î²2 arbitrarily close
or even equal to zero, which leads to the uncontrollability of the
estimated model and unboundness of u(t). To avoid this issue,
we propose a modification to the control law (17). One method
is to modify the adaptive law for Î²12 (t) so that adaptation takes
place in a subset of R which does not include the zero element.
We need to use the a priori knowledge of Î²1 â‰¥ Î²1lb > 0 and
Î²2 â‰¥ Î²2lb > 0 to do the projection:
uâˆ— (t) = âˆ’

Ë™
Î²Ìƒ 3 (t) = âˆ’Î³1 (yp (t) âˆ’ d(t))e(t)
â§
âª
Î³2 e(t)u(t), if |Î²Ìƒ12 (t)| > Î²1lb Î²2lb
âª
âª
âª
â¨
or |Î²Ìƒ12 (t)| = Î²1lb Î²2lb
Ë™
(18)
Î²Ìƒ 12 (t) =
âª
and e(t)u(t)sgn(Î²Ìƒ12 (t)) â‰¥ 0
âª
âª
âª
â©
0,
otherwise.
After modifying the adaptive control law, the time derivative of
the Lyapunov function becomes:
â§
âˆ’am (e(t))2 ,
if |Î²Ìƒ12 (t)| > Î²1lb Î²2lb
âª
âª
âª
âª
âª
âª
or |Î²Ìƒ12 (t)| = Î²1lb Î²2lb
âª
âª
âª
â¨
and e(t)u(t)sgn(Î²Ìƒ12 ) â‰¥ 0
VÌ‡ (t) =
2
âª âˆ’am (e(t))
âª
âª
âª
âª
âª
+Î²Ìƒ12 (t)e(t)u(t), if |Î²Ìƒ12 (t)| = Î²1lb Î²2lb
âª
âª
âª
â©
and e(t)u(t)sgn(Î²Ìƒ12 (t)) < 0.
Therefore, VÌ‡ (t) â‰¤ âˆ’am e2 (t) â‰¤ 0 âˆ€t â‰¥ t0 .
Using a similar argument as before, it can be shown that by
using this modified parameter estimation law (18), the tracking

error converges to zero driven by a bounded control signal. Additionally, we have shown (cf., Theorem III.1) that the reference
output response is exponentially stable, and it follows that the
system output can be driven to the stable state exponentially
fast.
We next test the indirect MRAC law using the patient data.
The parameter values of the reference model are the same as in
Section III-A. We choose the population-wide parameter values
Î²3âˆ— = 7.9 Ã— 10âˆ’4 and Î²1âˆ— Î²2âˆ— = 4.22 as initial values of Î²3 (t) and
Î²12 (t), respectively. The MRAC adapts based on these estimates
in real time. We also set Î³1 = Î³2 = 5 Ã— 10âˆ’4 . The trajectory of
the system under the indirect MRAC is shown in Fig. 6.
Fig. 6 indicates that the system output quickly converges to
the reference output, and it remains within the desired range
(top figure). The tracking error oscillates around zero (middle
figure), but it is not as smooth as in Fig. 4. This is due to the fact
that the indirect MRAC takes some time to estimate the system
parameters first and then adapts the controller coefficients. Similarly, we can also obtain the bivalirudin infusion rate (bottom
figure). Notice that although d(t) changes over time, the control
signal can drive the system to track the reference output signal
well. The performance of indirect MRAC for all patients in the
test set is reported in Table III.
We note that in this case, the values of our three performance
metrics are all higher than those in the Table I. This is again
explained by the fact that adaptation of the indirect MRAC law
is not very fast due to the parameter estimation step. Yet, RMSE,
NRMSE, and RP values are now significantly less than those in
Table II, and they could be considered acceptable in a clinical
setting.
C. Direct MRAC
In this section, we focus on designing the direct MRAC without estimating the model parameters first. Because the individual
model parameters are unknown, we cannot apply the MRC law
directly. Based on the structure of MRC law, we propose an
adaptive control law with similar structure:
k2 (t)r(t) âˆ’ 
k3 (t)d(t)
u(t) = âˆ’
k1 (t)yp (t) + 
where 
k1 (t), 
k2 (t), and 
k3 (t) are the estimates of MRC controller coefficients k1âˆ— , k2âˆ— , and k3âˆ— at time t, respectively. We will
devise a control law that estimates these coefficients directly.
Consider the error derivative:
eÌ‡(t) = yÌ‡p (t) âˆ’ yÌ‡m (t)
= âˆ’am e(t) + Î²1 Î²2 [âˆ’kÌƒ1 (t)yp (t)
+kÌƒ2 (t)r(t) âˆ’ kÌƒ3 (t)d(t)]
Ë™
ki (t) âˆ’ kiâˆ— , i = 1, 2, 3. It follows that 
k i (t) =
where kÌƒi (t) = 
Ë™
kÌƒ i (t), i = 1, 2, 3.
To design the controller, consider the Lyapunov-like function:

	
kÌƒ2 (t)2
kÌƒ3 (t)2
e(t)2
kÌƒ1 (t)2
+ Î²1 Î²2
+
+
V (t) =
.
2
2Î³1
2Î³2
2Î³3

ZHAO et al.: ADAPTIVE CONTROL OF BIVALIRUDIN IN THE CARDIAC INTENSIVE CARE UNIT

Fig. 6.

645

Performance of the indirect MRAC law.

TABLE III
PERFORMANCE OF THE INDIRECT MRAC (TEST SET)

By taking the derivative, we obtain
VÌ‡ (t)


	
Ë™
Ë™
Ë™
kÌƒ1 (t)kÌƒ 1 (t) kÌƒ2 (t)kÌƒ 2 (t) kÌƒ3 (t)kÌƒ 3 (t)
+
+
Î³1
Î³2
Î³3

kÌƒ1 (t) Ë™
= âˆ’am e2 (t) + Î²1 Î²2
(kÌƒ 1 (t) âˆ’ e(t)Î³1 yp (t))
Î³1
	
kÌƒ3 (t) Ë™
kÌƒ2 (t) Ë™
(kÌƒ 2 (t) + e(t)Î³2 r(t)) +
(kÌƒ 3 (t) âˆ’ e(t)Î³3 d(t))
+
Î³2
Î³3
= eÌ‡(t)e(t) + Î²1 Î²2

where we have the a priori knowledge that Î²1 Î²2 > 0.
Choosing
Ë™
kÌƒ 1 (t) = Î³1 e(t)yp (t)
Ë™
kÌƒ 2 (t) = âˆ’Î³2 e(t)r(t)
Ë™
kÌƒ 3 (t) = Î³3 e(t)d(t)
leads to VÌ‡ (t) = âˆ’am e(t)2 â‰¤ 0. Furthermore, the controller coefficients can be adapted by
Ë™

ki (t) + 
k i (t)Î”t,
ki (t + Î”t) = 

i = 1, 2, 3

and our direct MRAC controller becomes
u(t) = âˆ’
k1 (t)yp (t) + 
k2 (t)r(t) âˆ’ 
k3 (t)d(t).

(19)

As with the previous two controllers, we will use max{0, u(t)}
to avoid negative controls.
We establish the following result; we omit the proof because
it is similar to the proof of Theorem III.2.
Theorem III.3: Under the control law (19), the tracking error
converges to 0 as t â†’ âˆ.

value
RMSE
ÏƒE
NRMSE
ÏƒN E
RP

5.52
2.00
7.88%
2.86%
2.30%

We know that the reference model output is exponentially
stable, and the tracking error converges to zero as t increases,
which establishes that the system output can be driven to track
the reference output well. To avoid overdosing and underdosing
risks that may occur in the time it takes the MRAC to converge
to the appropriate controller parameters, we can use as initial
estimates of these coefficients the MRC coefficients, namely

k2 (0) = 165.75, and 
k3 (0) = 1.87 Ã— 10âˆ’4 , obk1 (0) = 2.37, 
tained from a system model parametrized with population-wide
parameters.
We applied such a direct MRAC law to the same patient
used for generating Fig. 6. The result is shown in Fig. 7 (using Î³1 = Î³2 = Î³3 = 0.001). We note that driven by the direct
MRAC law, the system output quickly converges to the reference
output. Although the system output oscillates around the reference signal, it remains within the desired range (top figure). The
tracking error also converges to zero (middle figure). We also
plot the bivalirudin infusion rate (bottom figure). Compared to
the indirect MRAC, the direct MRAC has similar performance
on controlling the PTT. However, the direct MRAC avoids parameter estimation and estimates controller parameters directly.

646

Fig. 7.

IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, VOL. 62, NO. 2, FEBRUARY 2015

Performance of direct MRAC law.

TABLE IV
PERFORMANCE OF THE DIRECT MRAC (TEST SET)
value
RMSE
ÏƒE
NRMSE
ÏƒN E
RP

0.80
0.80
1.15%
1.14%
0.09%

Table IV reports the overall performance of the direct MRAC
for the patients in the test set. Compared to the results from the
indirect MRAC, the direct MRAC achieves lower values for all
performance metrics, i.e., RMSE, NRMSE, ÏƒE , ÏƒNE , and RP.
Notice the rather significant decrease of the RP value, which,
as we argued, is clinically a top priority. This table validates the
fact that the direct MRAC is a more efficient and safer control
scheme than the indirect MRAC.
IV. CONCLUSION
Based on a specific dynamic system model of bivalirudin
acting in cardiac surgical patients, we developed two methods
for synthesizing a controller to regulate the bivalirudin infusion
rate and induce a PTT within a desirable range. The first method
assumes that the model parameters are available and develops
a control law that tracks a physician specified reference output
signal. Our second method considers patients for which past
clinical records are sparse and accurate model parameters are
not readily available. It develops an indirect control scheme
(indirect MRAC) that first estimates the model parameters and
then adapts the corresponding controller based on these esti-

mates. Alternatively, a direct control scheme (direct MRAC)
that adapts the controller without estimating the model parameters first is also developed. Testing of these schemes against
actual patient data from a hospital shows that the direct MRAC
is more efficient than the indirect version.
The methods we developed can be seen as key steps toward
automation of dosage decisions in a hospital setting, which can
help eliminate errors and neutralize the inexperience of residents
who are currently responsible for these decisions.
APPENDIX
The solution to (5) is


t

ym (t) = Î¦(t, t0 )ym (t0 ) +

Î¦(t, Ï„ )bm r(Ï„ )dÏ„
t0

where Î¦(t, Ï„ ) = eâˆ’a m (tâˆ’Ï„ ) is the state transition function in this
problem. Since r(t) = Cr , which is a constant, the solution to
(5) can be written as


bm Cr
bm Cr
ym (t; t0 , ym (t0 )) = eâˆ’a m (tâˆ’t 0 ) ym (t0 ) âˆ’
.
+
am
am
(20)
Equation (20) indicates that ym (t; t0 , ym (t0 )) â†’ b ma mC r which
is a constant, as t â†’ âˆ. In addition, using Definition 1, it can
be easily verified that ym e = b ma mC r is the equilibrium state of
our reference system. Furthermore, |ym (t; t0 , ym (t0 )) âˆ’ ym e |=
|eâˆ’a m (tâˆ’t 0 ) (ym (t0 ) âˆ’ ym e )|= |ym (t0 ) âˆ’ ym e | eâˆ’a m (tâˆ’t 0 ) âˆ€t â‰¥
t0 . Therefore, by Definition 2, it follows that the reference model
equilibrium state ym e is exponentially stable.

ZHAO et al.: ADAPTIVE CONTROL OF BIVALIRUDIN IN THE CARDIAC INTENSIVE CARE UNIT

REFERENCES
[1] Q. Zhao, T. Edrich, and I. C. Paschalidis, â€œPredicting and evaluating the
effect of bivalirudin in cardiac surgical patients,â€ IEEE Trans. Biomed.
Eng., vol. 61, no. 2, pp. 435â€“443, Jan. 2014.
[2] J. Bittl, B. Chaitman, F. Feit, W. Kimball, and E. Topol, â€œBivalirudin
versus heparin during coronary angioplasty for unstable or postinfarction
angina: Final report reanalysis of the bivalirudin angioplasty study,â€ Amer.
Heart J., vol. 142, no. 6, pp. 952â€“959, 2001.
[3] A. Lincoff, J. Bittl, R. Harrington, F. Feit, N. Kleiman, J. Jackman,
I. Sarembock, D. Cohen, D. Spriggs, R. Ebrahimi, G. Keren, J. Carr,
E. Cohen, A. Betriu, W. Desmet, D. Kereiakes, W. Rutsch, R. Wilcox,
P. J. de Feyter, A. Vahanian, and E. Topol, â€œBivalirudin and provisional
glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention,â€ J.
Amer. Med. Assoc., vol. 289, no. 7, pp. 853â€“863, 2003.
[4] G. Stone, B. McLaurin, D. Cox, M. Bertrand, A. Lincoff, J. Moses,
H. White, S. Pocock, J. Ware, F. Feit, A. Colombo, P. Aylward,
A. Cequier, H. Darius, W. Desmet, R. Ebrahimi, M. Hamon, L. Rasmussen,
H.-J. Rupprecht, J. Hoekstra, R. Mehran, and E. Ohman, â€œBivalirudin for
patients with acute coronary syndromes,â€ New Engl. J. Med., vol. 355,
no. 21, pp. 2203â€“2216, 2006.
[5] T. M. Company, â€œAngiomax (bivalirudin) Prescribing Information,â€ [Online]. Available: http://www.themedicinescompany.com/page/angiomaxus/1, 2011.
[6] T. H. Kiser, A. M. Mann, T. C. Trujillo, and K. L. Hassell, â€œEvaluation of
empiric versus nomogram-based direct thrombin inhibitor management
in patients with suspected heparin-induced thrombocytopenia,â€ Amer.
J. Hematol., vol. 86, no. 3, pp. 267â€“272, 2011.
[7] T. Edrich, G. Frendl, and I. C. Paschalidis, â€œTachyphylaxis in post-cardiac
surgical patients receiving bivalirudinâ€”A retrospective dynamic study
using a PKPD model,â€ Crit. Care Med., vol. 39, no. 12, p. 198, Dec. 2011.
[8] Q. Zhao, T. Edrich, and I. C. Paschalidis, â€œA predictive model for the
anticoagulant bivalirudin administered to cardiac surgical patients,â€ in
Proc. 52nd IEEE Conf. Decision Control, Florence, Italy, Dec. 2013,
pp. 121â€“126.
[9] J. R. Jacobs and E. A. Williams, â€œAlgorithm to control â€effect compartmentâ€ drug concentrations in pharmacokinetic model-driven drug delivery,â€ IEEE Trans. Biomed. Eng., vol. 40, no. 10, pp. 993â€“999, Oct. 1993.
[10] C. M. Ionescu, R. Hodrea, and R. De Keyser, â€œVariable time-delay estimation for anesthesia control during intensive care,â€ IEEE Trans. Biomed.
Eng., vol. 58, no. 2, pp. 363â€“369, Jan. 2011.
[11] C. Held and R. J. Roy, â€œMultiple drug hemodynamic control by means
of a supervisory-fuzzy rule-based adaptive control system: Validation
on a model,â€ IEEE Trans. Biomed. Eng., vol. 42, no. 4, pp. 371â€“385,
Apr. 1995.
[12] D. Bertsekas, Nonlinear Programming, 2nd ed. Belmont, MA, USA:
Athena Scientific, 1999.
[13] P. A. Ioannou and E. B. Kosmatopoulos, Adaptive Control. New York,
NY, USA: Wiley, 2006.
[14] P. A. Ioannou and J. Sun, Robust Adaptive Control. New York, NY, USA:
Dover, 2012.
[15] V. M. Popov and R. Georgescu, Hyperstability of Control Systems. New
York, NY, USA: Springer-Verlag, Inc., 1973.

647

Qi Zhao received the B.S. degree in electrical engineering and automation from the University of Science and Technology, Beijing, China, in 2010, and the
M.S. degree in electrical engineering from Boston
University, Boston, MA, USA, in 2012. He is currently working toward the Ph.D. degree in the Division of Systems Engineering, Boston University. His
current research interests include the fields of systems and control, optimization, operations research,
computational biology, and bioinformatics.

Thomas Edrich (Mâ€™11) received the B.S. degree
in electrical engineering at the University of Colorado at Boulder, Boulder, CO, USA, in 1992, and
the M.D. and Ph.D. degrees at Ludwig-Maximilians
University, Munich, Germany, in 1996 and 1999,
respectively.
He is specialized in Anesthesia and Critical Care
Medicine. He is currently an Anesthesiologist affiliated with both the Department of Anesthesia,
Brigham and Womenâ€™s Hospital, Harvard Medical
School, Boston, MA, USA, as well as the Salzburg
General Hospital in Austria. His research interests include the fields of
PKPD modeling, medical control systems, as well as, critical care ultrasound
applications.

Ioannis Ch. Paschalidis (Mâ€™96â€“SMâ€™06â€“Fâ€™14) received the M.S. and Ph.D. degrees both in electrical engineering and computer science from the
Massachusetts Institute of Technology (MIT), Cambridge, MA, USA, in 1993 and 1996, respectively.
Since September 1996, he has been with Boston
University, Boston, MA. He is a Professor and Distinguished Faculty Fellow at Boston University with appointments in the Department of Electrical and Computer Engineering, the Division of Systems Engineering, and the Department of Biomedical Engineering.
He is the Director of the Center for Information and Systems Engineering.
He has held visiting appointments with MIT and Columbia University, New
York, NY, USA. His current research interests include the fields of systems
and control, networking, applied probability, optimization, operations research,
computational biology, and medical informatics.

